Back to top
more

Ultragenyx Pharmaceutical (RARE)

(Delayed Data from NSDQ)

$50.36 USD

50.36
1,246,770

-0.07 (-0.14%)

Updated Nov 8, 2024 04:00 PM ET

After-Market: $50.32 -0.04 (-0.08%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Why Is Denali Therapeutics Inc. (DNLI) Up 11.9% Since Last Earnings Report?

by Zacks Equity Research

Denali Therapeutics Inc. (DNLI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Ultragenyx (RARE) Posts Data From Osteogenesis Imperfecta Study

by Zacks Equity Research

Ultragenyx (RARE), along with partner Mereo BioPharma, announces encouraging data on mid-stage study evaluating setrusumab for patients with osteogenesis imperfecta.

Ultragenyx's (RARE) GTX-102 Gets FDA Nod for Uniform Dosing

by Zacks Equity Research

Ultragenyx (RARE) stock climbs 5% after the FDA agrees to a protocol amendment to the phase I/II study of GTX-102 in pediatric patients with Angelman syndrome.

Ultragenyx (RARE) Q1 Earnings and Revenues Miss Estimates

by Zacks Equity Research

Ultragenyx Pharmaceutical's (RARE) first-quarter 2023 earnings and revenues miss estimates. The company maintains its 2023 guidance.

Ultragenyx (RARE) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Ultragenyx (RARE) delivered earnings and revenue surprises of -18.27% and 4.06%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Allogene Therapeutics (ALLO) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Allogene Therapeutics (ALLO) delivered earnings and revenue surprises of -7.94% and 35%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Will Zymeworks Inc. (ZYME) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

Zymeworks Inc. (ZYME) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ultragenyx (RARE) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

by Zacks Equity Research

Ultragenyx (RARE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Strength Seen in Ultragenyx (RARE): Can Its 6.7% Jump Turn into More Strength?

by Zacks Equity Research

Ultragenyx (RARE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Emergent Biosolutions (EBS) Surges 5.1%: Is This an Indication of Further Gains?

by Zacks Equity Research

Emergent Biosolutions (EBS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Ultragenyx (RARE) Q4 Earnings Miss, Revenues Increase Y/Y

by Zacks Equity Research

Ultragenyx (RARE) reports a wider loss in the fourth quarter while revenues increase on growth in demand for its drugs.

Ultragenyx (RARE) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Ultragenyx (RARE) delivered earnings and revenue surprises of -6.40% and 0.27%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Drug/Biotech Stocks Q4 Earnings Due on Feb 16: ALKS, RARE & Others

by Zacks Equity Research

Let's look at the four biotech/drug companies slated to release quarterly results on Feb 16.

Exact Sciences (EXAS) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

by Zacks Equity Research

Exact Sciences (EXAS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ultragenyx (RARE) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

by Zacks Equity Research

Ultragenyx (RARE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Amgen (AMGN) Surpasses Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Amgen (AMGN) delivered earnings and revenue surprises of 1.24% and 1.49%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Strength Seen in Exact Sciences (EXAS): Can Its 24.7% Jump Turn into More Strength?

by Zacks Equity Research

Exact Sciences (EXAS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Ultragenyx (RARE) Posts Preliminary '22 Results, Gives '23 View

by Zacks Equity Research

Ultragenyx (RARE) reports preliminary product revenues for its marketed drugs, Crysvita, Mepsevii and Dojolvi for the full year 2022. The company issues product revenue guidance for 2023.

Ultragenyx's (RARE) Portfolio of Marketed Drugs Aids Growth

by Zacks Equity Research

Ultragenyx's (RARE) marketed drugs, which are approved for various indications, are driving the top line. The company also has a strong pipeline. However, pipeline setbacks remain concerning.

Why Is Bluebird (BLUE) Up 6.2% Since Last Earnings Report?

by Zacks Equity Research

Bluebird (BLUE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Ultragenyx (RARE) Down 0.9% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Ultragenyx (RARE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Regeneron's (REGN) sBLA for Evkeeza Gets FDA Priority Review

by Zacks Equity Research

The FDA accepts for priority review Regeneron's (REGN) sBLA for Evkeeza for treating children aged five to 11 years with homozygous familial hypercholesterolemia. A decision is due on Mar 30, 2023.

Ultragenyx's (RARE) Q3 Earnings Miss Estimates, Revenues Up Y/Y

by Zacks Equity Research

Ultragenyx (RARE) reports a wider-than-expected loss in the third quarter. Revenues, though up year over year, miss estimates.

Ultragenyx (RARE) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Ultragenyx (RARE) delivered earnings and revenue surprises of -6.11% and 8.16%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

CRISPR Therapeutics AG (CRSP) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

CRISPR Therapeutics AG (CRSP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.